ArticleBioMed research international2026
Comparative Biocompatibility of Portland-Based Endodontic Cements Containing Niobium and/or Bismuth Oxides in Rat Subcutaneous Tissue.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Biocompatibility of Portland-Based Endodontic Cements Containing Niobium and/or Bismuth Oxides in Rat Subcutaneous Tissue.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectivesTo evaluate the in vitro cytocompatibility and osteogenic potential and the in vivo biocompatibility of two experimental endodontic cements based on Portland cement combined with either Nb2O
methodsFor the in vitro study, MC3T3-E1 preosteoblastic cells were exposed to MTA Angelus, F6, or F7, and cell viability was assessed at 24 and 48 h using the Alamar Blue assay. Osteogenic differentiation was evaluated by alkaline phosphatase (ALP) activity after 14 days. For the in vivo analysis, polyethylene tubes containing the materials were implanted into the dorsal subcutaneous tissue of rats and evaluated at 7, 14, and 30 days, with empty tubes used as controls. Histological and histochemical analyses included hematoxylin and eosin (H&E), Picrosirius Red, Von Kossa staining, and TNF-α immunohistochemistry. Chemical characterization was performed using Raman spectroscopy and X-ray fluorescence (XRF). In vitro data were analyzed using one-way ANOVA followed by Tukey's post hoc test, while semiquantitative histological data were analyzed using the Kruskal-Wallis test followed by Dunn's test. A significance level of 5% (p < 0.05) was adopted.
resultsIn vitro, F6 showed cell viability comparable to MTA Angelus at both 24 h (36.22 ± 2.66% vs. 35.75 ± 1.18%) and 48 h (34.18 ± 3.09% vs. 35.20 ± 2.35%) (p > 0.05). In contrast, F7 significantly reduced cell viability at 24 h (25.61 ± 1.11%) compared with MTA Angelus (p = 0.002), although no difference was observed at 48 h (p > 0.05). ALP activity after 14 days did not differ significantly among MTA Angelus (1.90 ± 1.23 UI/L/g), F6 (1.71 ± 0.88 UI/L/g), and F7 (1.78 ± 1.34 UI/L/g) (p = 0.703). In vivo, F6 induced mild to moderate inflammatory responses at the early time period, with a significant reduction by Day 14 and minimal inflammation at Day 30, comparable to MTA Angelus. No multinucleated giant cells were observed, and TNF-α expression was moderate. Von Kossa staining and XRF confirmed calcium deposition, while Raman spectroscopy detected niobium species in peri-implant tissues, indicating bioactivity. Picrosirius Red staining demonstrated progressive collagen fiber organization. Conversely, F7 elicited a pronounced and persistent inflammatory response characterized by multinucleated giant cells, intense TNF-α expression, and bismuth retention in surrounding tissues, as confirmed by XRF, with no niobium-related signals detected by Raman analysis.
conclusionThe niobium-containing cement (F6) demonstrated favorable in vitro cytocompatibility and in vivo biocompatibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.